Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of…

By E. Chung, M. Packer, K. Lo, A. Fasanmade, J. Willerson. Circulation, 2003

1,495 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Immunology

View Paper: https://www.semanticscholar.org/paper/1ee3224b065ad386842df21136082bb2b14b8e53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Dixon
2. K. Watson
3. M. Lunt
4. K. Hyrich
5. D. Symmons
6. A. Silman

Citations in the corpus

• Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register (2007, result): “Contrary to expectations, 2 studies of etanercept had to be terminated early when interim analysis showed a lack of efficacy (30), and high-dose infliximab was shown to be detrimental in patients with moderate to severe chronic heart failure (31).”